Plasma Concentrations of Isosorbide Dinitrate and Its Metabolites After Chronic High Oral Dosage in Man

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1978 Jul 1

PMID 666946

Citations 9

Authors

S J SHANE

J J Iazzetta

A W Chisholm

J F Berka

D Leung

Affiliations

Soon will be listed here.

Abstract

1 We have previously reported that vasodilator headache due to isosorbide dinitrate (ISDN) can be circumvented by using small 'priming' doses for an induction period of 1-2 weeks, after which it is possible to increase to dose rapidly to 360-720 mg, daily without recurrence of headache and without toxicity. The present study corroborates this earlier finding. 2. Chronic oral administration of doses of ISDN of this order of magnitude results in prolonged high plasma concentrations of the parent compound, as well as higher levels of the metabolites 2-ISMN and 5-ISMN. 3. It is our thesis that chronic high oral dosage of ISDN saturates the intrahepatic biotransformation process, and allows high concentrations of ISDN and its metabolites to enter the systemic circulation.

Citing Articles

Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.

Jorgensen L, Thaulow E, Bredesen J, REFSUM H Clin Cardiol. 2000; 23(6):427-32.

PMID: 10875033 PMC: 6655186. DOI: 10.1002/clc.4960230610.

Effects and pharmacokinetics of isosorbide dinitrate in normal man.

BETZIEN G, Kaufmann B, Liede V, Abshagen U Eur J Clin Pharmacol. 1980; 18(3):237-44.

PMID: 7439242 DOI: 10.1007/BF00563005.

Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Bogaert M, Rosseel M, Boelaert J, DANEELS R Eur J Clin Pharmacol. 1981; 21(1):73-6.

PMID: 7333349 DOI: 10.1007/BF00609591.

Kinetics of isosorbide dinitrate and relationships to pharmacological effects.

Fung H, McNiff E, Ruggirello D, Darke A, Thadani U, PARKER J Br J Clin Pharmacol. 1981; 11(6):579-89.

PMID: 7272174 PMC: 1402196. DOI: 10.1111/j.1365-2125.1981.tb01174.x.

A standard approach to compiling clinical pharmacokinetic data.

Sheiner L, Benet L, Pagliaro L J Pharmacokinet Biopharm. 1981; 9(1):59-127.

PMID: 7014827 DOI: 10.1007/BF01059343.

References

Chasseaud L, Down W, Grundy R . Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. Eur J Clin Pharmacol. 1975; 8(3-4):157-60. DOI: 10.1007/BF00567108. View

Bogaert M, Rosseel M . Vascular effects of the dinitrate and moninitrate esters of isosorbide, isomannide and isoidide. Naunyn Schmiedebergs Arch Pharmacol. 1972; 275(3):339-42. DOI: 10.1007/BF00500061. View

NEEDLEMAN P . Organic nitrate metabolism. Annu Rev Pharmacol Toxicol. 1976; 16:81-93. DOI: 10.1146/annurev.pa.16.040176.000501. View

Parker J, DI CARLO F, DAVIDSON I . Comparative vasodilator effects of nitroglycerin, pentaerythritol trinitrate and biometabolites, and other organic nitrates. Eur J Pharmacol. 1975; 31(1):29-37. DOI: 10.1016/0014-2999(75)90075-8. View

Bogaert M, Rosseel M, De Schaepdryver A . The metabolic fate of nitroglycerin (trinitrin) in relation to its vascular effects. Eur J Pharmacol. 1970; 12(2):224-30. DOI: 10.1016/0014-2999(70)90068-3. View